We have located links that may give you full text access.
Journal Article
Review
Targeting STAT1 in Both Cancer and Insulin Resistance Diseases.
With the rapid development of targeted therapy and our understanding of the underlying molecular mechanisms, drug repurposing is becoming trendy in drug development field. Drugs that display promising therapeutic effects towards multiple diseases tend to target important signaling proteins. Insulin resistance and obesity are strongly associated and both are reported to be correlated with cancer, suggesting they may be linked via some critical pathways. Signal transducer and activator of transcription 1 (STAT1) is an important transcription factor involved in the regulation of multiple cellular processes such as proliferation, survival, inflammation, and angiogenesis. The expression and activity of STAT1 is misregulated in both insulin resistance diseases and cancer. In this review, we summarize recent progress on the function and regulation of STAT1 in both cancer and insulin resistance diseases. Drugs and small molecules that can interfere with STAT1 activity or expression are also discussed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app